Division of BRF
Center for Molecular Imaging & Therapy
Research Center Based in Shreveport, Louisiana
Research Center Based in Shreveport, Louisiana
About Us
About Us
About Us
Theranostic Research Center
The Center for Molecular Imaging and Therapy (CMIT) is a comprehensive molecular imaging & therapy research center housing clinical and pre-clinical PET/CT imaging, research laboratories, and radiopharmaceutical manufacturing based in Shreveport, Louisiana, USA.
0+
0+
Skilled Professionals
Serving the industry
0+
0+
Skilled Professionals
Serving the industry
0+
0+
Skilled Professionals
Serving the industry
0
0
Years Experience
Pioneering molecular imaging and therapy
0
0
Years Experience
Pioneering molecular imaging and therapy
0
0
Years Experience
Pioneering molecular imaging and therapy
0
0
States
Coast to coast theranostic research and care
0
0
States
Coast to coast theranostic research and care
0
0
States
Coast to coast theranostic research and care
0k+
0k+
Scans
Over 50,000 clinical & research scans to date
0k+
0k+
Scans
Over 50,000 clinical & research scans to date
0k+
0k+
Scans
Over 50,000 clinical & research scans to date
Our Reach
Our Reach
Our Reach
15 States & Counting
Coast to coast theranostic research and care
Services
Services
Services
What we do
Full-service molecular imaging research center housing clinical and pre-clinical PET/CT imaging, research laboratories, with radiopharmaceutical and targeted radiotherapy manufacturing based in Shreveport, Louisiana, USA.
01
Pre-Clinical
CMIT advances early-stage drug discovery with comprehensive research capabilities. Our facility includes a vivarium, PET and SPECT imaging, optical imaging, and nine specialized labs for chemistry, tissue culture, and biodistribution. We help partners move from concept to clinical application with precision and efficiency.
Pre-Clinical
CMIT advances early-stage drug discovery with comprehensive research capabilities. Our facility includes a vivarium, PET and SPECT imaging, optical imaging, and nine specialized labs for chemistry, tissue culture, and biodistribution. We help partners move from concept to clinical application with precision and efficiency.
Pre-Clinical
CMIT advances early-stage drug discovery with comprehensive research capabilities. Our facility includes a vivarium, PET and SPECT imaging, optical imaging, and nine specialized labs for chemistry, tissue culture, and biodistribution. We help partners move from concept to clinical application with precision and efficiency.
Manufacturing
CMIT produces a full range of diagnostic and therapeutic radiopharmaceuticals on site using compliant labs, a dedicated cyclotron, and an in-house nuclear pharmacy. We offer contract production, quality control testing, and national distribution to support research and clinical needs with speed and reliability.
Manufacturing
CMIT produces a full range of diagnostic and therapeutic radiopharmaceuticals on site using compliant labs, a dedicated cyclotron, and an in-house nuclear pharmacy. We offer contract production, quality control testing, and national distribution to support research and clinical needs with speed and reliability.
Manufacturing
CMIT produces a full range of diagnostic and therapeutic radiopharmaceuticals on site using compliant labs, a dedicated cyclotron, and an in-house nuclear pharmacy. We offer contract production, quality control testing, and national distribution to support research and clinical needs with speed and reliability.
02
03
Clinical Imaging & Therapy
CMIT delivers high-quality imaging through advanced PET and CT systems designed for both clinical care and research. Our imaging services support everything from diagnosis and therapy planning to data collection for trials, providing accurate and consistent results that drive better decisions.
Clinical Imaging & Therapy
CMIT delivers high-quality imaging through advanced PET and CT systems designed for both clinical care and research. Our imaging services support everything from diagnosis and therapy planning to data collection for trials, providing accurate and consistent results that drive better decisions.
Clinical Imaging & Therapy
CMIT delivers high-quality imaging through advanced PET and CT systems designed for both clinical care and research. Our imaging services support everything from diagnosis and therapy planning to data collection for trials, providing accurate and consistent results that drive better decisions.
Our Work
Our Work
Our Work
Serving the Industry
Driving progress through partnerships, clinical trials, and radiopharmaceutical breakthroughs.
Ochsner LSU Partnership
CMIT serves as an imaging partner for Ochsner LSU’s health centers in North Louisiana. The partnership expands patient access to state-of-the-art diagnostic and therapeutic imaging and cutting edge clinical trials
Ochsner LSU Partnership
CMIT serves as an imaging partner for Ochsner LSU’s health centers in North Louisiana. The partnership expands patient access to state-of-the-art diagnostic and therapeutic imaging and cutting edge clinical trials
Ochsner LSU Partnership
CMIT serves as an imaging partner for Ochsner LSU’s health centers in North Louisiana. The partnership expands patient access to state-of-the-art diagnostic and therapeutic imaging and cutting edge clinical trials
Cook Children’s Medical Center Collaboration
CMIT provides specialized radiopharmaceuticals to detect hyperinsulinism in infants at Cook Children’s Medical Center in Fort Worth, Texas. The Cook Children’s Hyperinsulinism Center is one of six Centers of Excellence in the world designated by Congenital Hyperinsulinism International.
Cook Children’s Medical Center Collaboration
CMIT provides specialized radiopharmaceuticals to detect hyperinsulinism in infants at Cook Children’s Medical Center in Fort Worth, Texas. The Cook Children’s Hyperinsulinism Center is one of six Centers of Excellence in the world designated by Congenital Hyperinsulinism International.
Cook Children’s Medical Center Collaboration
CMIT provides specialized radiopharmaceuticals to detect hyperinsulinism in infants at Cook Children’s Medical Center in Fort Worth, Texas. The Cook Children’s Hyperinsulinism Center is one of six Centers of Excellence in the world designated by Congenital Hyperinsulinism International.
LSU Health Shreveport Partnership
CMIT is a co-investigator on a pilot project using C-11 radiopharmaceutical to assist in a stimulant use disorder study, assessing the persistent behavioral and neurochemical effects of exposure to various classes of stimulants. The research aims to identify novel drug targets to prevent devastating adverse events associated with stimulant overdose.
LSU Health Shreveport Partnership
CMIT is a co-investigator on a pilot project using C-11 radiopharmaceutical to assist in a stimulant use disorder study, assessing the persistent behavioral and neurochemical effects of exposure to various classes of stimulants. The research aims to identify novel drug targets to prevent devastating adverse events associated with stimulant overdose.
LSU Health Shreveport Partnership
CMIT is a co-investigator on a pilot project using C-11 radiopharmaceutical to assist in a stimulant use disorder study, assessing the persistent behavioral and neurochemical effects of exposure to various classes of stimulants. The research aims to identify novel drug targets to prevent devastating adverse events associated with stimulant overdose.
Team
Team
Team
CMIT Leadership
Our strength lies in the dedicated team of scientists, clinicians, and specialists pushing the field forward.
Stephen Lokitz, Ph.D
Executive Director
Stephen Lokitz, Ph.D
Executive Director
Stephen Lokitz, Ph.D
Executive Director
Rachid Nazih, Ph.D
Radiopharmaceutical Sciences Director
Rachid Nazih, Ph.D
Radiopharmaceutical Sciences Director
Rachid Nazih, Ph.D
Radiopharmaceutical Sciences Director
Administration
John F. George M.D.
President and CEO / BRF
John F. George M.D.
President and CEO / BRF
John F. George M.D.
President and CEO / BRF
Jim Dean
Executive Vice President and COO / BRF
Jim Dean
Executive Vice President and COO / BRF
Jim Dean
Executive Vice President and COO / BRF
Michael Mazur
CFO / BRF
Michael Mazur
CFO / BRF
Michael Mazur
CFO / BRF
Hilary Wooley
Corporate Counsel / BRF
Hilary Wooley
Corporate Counsel / BRF
Hilary Wooley
Corporate Counsel / BRF
Sarah McCall
Director of Grants / BRF
Sarah McCall
Director of Grants / BRF
Sarah McCall
Director of Grants / BRF
Morgan Patrick
Director of Philanthropy / BRF
Morgan Patrick
Director of Philanthropy / BRF
Morgan Patrick
Director of Philanthropy / BRF
Courtney Bryan
Director of Public Relations / BRF
Courtney Bryan
Director of Public Relations / BRF
Courtney Bryan
Director of Public Relations / BRF
Brian Williams
Assistant Director of Public Relations and Communications / BRF
Brian Williams
Assistant Director of Public Relations and Communications / BRF
Brian Williams
Assistant Director of Public Relations and Communications / BRF
FAQs
FAQs
FAQs
Answering your questions
Answering your questions
Answering your questions
More questions? Reach out to us.
More questions? Reach out to us.
More questions? Reach out to us.
What is CMIT?
The Center for Molecular Imaging and Therapy is an independent research organization with the mission to advance and perform molecular imaging research.
What is molecular imaging?
Molecular imaging is a group of procedures that uses molecular probes to provide functional information about the patient or subject being imaged. This is complimentary to imaging techniques such as MRI or CT which provide anatomic information by measuring density or water content. Molecular imaging is a critical component of healthcare for many diseases and provides very exciting research opportunities.
Do you offer free options?
CMIT has expertise in all areas of molecular imaging but focuses on the positron emission tomography (PET) modality. CMIT has expertise in the development, optimization and manufacturing of radiopharmaceuticals, the use of radiopharmaceuticals in the clinical and research environment, and the assessment of the value and results of the use of radiopharmaceuticals in both the clinical and research environments.
What is a radiopharmaceutical?
A radiopharmaceutical is a drug that contains a small amount of radioactivity and is used for diagnostic or therapeutic purposes. CMIT is engaged in radiopharmaceutical science research. Specifically, the team has the experience and expertise to optimize radiochemistry synthesis, develop novel diagnostic and therapeutic agents, and perform large scale production of molecular imaging probes. Through CMIT’s manufacturing and distribution laboratories, CMIT provides radiopharmaceuticals for clinical and research applications.
What is PET Imaging?
PET imaging uses specific radiopharmaceuticals to produce images which contain information helpful for clinical and research applications. The information explored by a given PET imaging procedure depends upon the specific radiopharmaceutical used. CMIT offers procedures for a variety of oncology, neurology and cardiology indications using multiple in-house available radiopharmaceuticals. CMIT is also engaged in several clinical trials to understand diseases such as Alzheimer’s disease and prostate cancer.
What research is CMIT performing?
CMIT is focused on developing novel radiopharmaceuticals and investigating new applications of these radiopharmaceuticals for molecular imaging and therapy. CMIT has specialized facilities that includes radiochemistry research laboratories, biology laboratories, translational research facilities, cyclotron facilities, and clinical imaging facilities.
What is CMIT?
The Center for Molecular Imaging and Therapy is an independent research organization with the mission to advance and perform molecular imaging research.
What is molecular imaging?
Molecular imaging is a group of procedures that uses molecular probes to provide functional information about the patient or subject being imaged. This is complimentary to imaging techniques such as MRI or CT which provide anatomic information by measuring density or water content. Molecular imaging is a critical component of healthcare for many diseases and provides very exciting research opportunities.
Do you offer free options?
CMIT has expertise in all areas of molecular imaging but focuses on the positron emission tomography (PET) modality. CMIT has expertise in the development, optimization and manufacturing of radiopharmaceuticals, the use of radiopharmaceuticals in the clinical and research environment, and the assessment of the value and results of the use of radiopharmaceuticals in both the clinical and research environments.
What is a radiopharmaceutical?
A radiopharmaceutical is a drug that contains a small amount of radioactivity and is used for diagnostic or therapeutic purposes. CMIT is engaged in radiopharmaceutical science research. Specifically, the team has the experience and expertise to optimize radiochemistry synthesis, develop novel diagnostic and therapeutic agents, and perform large scale production of molecular imaging probes. Through CMIT’s manufacturing and distribution laboratories, CMIT provides radiopharmaceuticals for clinical and research applications.
What is PET Imaging?
PET imaging uses specific radiopharmaceuticals to produce images which contain information helpful for clinical and research applications. The information explored by a given PET imaging procedure depends upon the specific radiopharmaceutical used. CMIT offers procedures for a variety of oncology, neurology and cardiology indications using multiple in-house available radiopharmaceuticals. CMIT is also engaged in several clinical trials to understand diseases such as Alzheimer’s disease and prostate cancer.
What research is CMIT performing?
CMIT is focused on developing novel radiopharmaceuticals and investigating new applications of these radiopharmaceuticals for molecular imaging and therapy. CMIT has specialized facilities that includes radiochemistry research laboratories, biology laboratories, translational research facilities, cyclotron facilities, and clinical imaging facilities.
What is CMIT?
The Center for Molecular Imaging and Therapy is an independent research organization with the mission to advance and perform molecular imaging research.
What is molecular imaging?
Molecular imaging is a group of procedures that uses molecular probes to provide functional information about the patient or subject being imaged. This is complimentary to imaging techniques such as MRI or CT which provide anatomic information by measuring density or water content. Molecular imaging is a critical component of healthcare for many diseases and provides very exciting research opportunities.
Do you offer free options?
CMIT has expertise in all areas of molecular imaging but focuses on the positron emission tomography (PET) modality. CMIT has expertise in the development, optimization and manufacturing of radiopharmaceuticals, the use of radiopharmaceuticals in the clinical and research environment, and the assessment of the value and results of the use of radiopharmaceuticals in both the clinical and research environments.
What is a radiopharmaceutical?
A radiopharmaceutical is a drug that contains a small amount of radioactivity and is used for diagnostic or therapeutic purposes. CMIT is engaged in radiopharmaceutical science research. Specifically, the team has the experience and expertise to optimize radiochemistry synthesis, develop novel diagnostic and therapeutic agents, and perform large scale production of molecular imaging probes. Through CMIT’s manufacturing and distribution laboratories, CMIT provides radiopharmaceuticals for clinical and research applications.
What is PET Imaging?
PET imaging uses specific radiopharmaceuticals to produce images which contain information helpful for clinical and research applications. The information explored by a given PET imaging procedure depends upon the specific radiopharmaceutical used. CMIT offers procedures for a variety of oncology, neurology and cardiology indications using multiple in-house available radiopharmaceuticals. CMIT is also engaged in several clinical trials to understand diseases such as Alzheimer’s disease and prostate cancer.
What research is CMIT performing?
CMIT is focused on developing novel radiopharmaceuticals and investigating new applications of these radiopharmaceuticals for molecular imaging and therapy. CMIT has specialized facilities that includes radiochemistry research laboratories, biology laboratories, translational research facilities, cyclotron facilities, and clinical imaging facilities.
Contact
Get in touch
We’re here to support patient access to diagnostic and therapeutic radiopharmaceuticals and imaging. We also support partners’ research, clinical and manufacturing needs. Reach out to us with questions about our capabilities and our team.
Contact
Get in touch
We’re here to support patient access to diagnostic and therapeutic radiopharmaceuticals and imaging. We also support partners’ research, clinical and manufacturing needs. Reach out to us with questions about our capabilities and our team.
Contact
Get in touch
We’re here to support patient access to diagnostic and therapeutic radiopharmaceuticals and imaging. We also support partners’ research, clinical and manufacturing needs. Reach out to us with questions about our capabilities and our team.